New drug to treat HIV complication approved by FDA

The U.S. Food and Drug Administration has announced its approval of Egrifta, a drug designed to treat lipodystrophy, an effect of HIV.

Lipodystrophy occurs when excess fat cells accumulate in certain regions of the body, which in HIV patients typically include the liver, stomach and abdominal organs. According to the FDA, the addition of fat around these organs can lead to further health complications.

The new medication, an injectable growth hormone release factor, reduces the fat growth associated lipodystrophy, the agency said.

Egrifta is the latest in a growing number of prescription medications designed to combat the side effects of HIV, which can include tuberculosis, hepatitis, toxoplasmosis, liver or kidney damage and urinary tract infections, according to the Mayo Clinic.

The FDA emphasizes the importance of early detection in treating the effects of HIV as well as in preventing the spread of the virus.

Those concerned that they have contracted HIV or another STD may consider looking into online testing services in order to determine the state of their sexual health. More than 56,000 Americans become infected with HIV every year, according to the Centers for Disease Control and Prevention.